A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Trial Profile

A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Grifols
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Oct 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
    • 14 Oct 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top